Regeneron Pharmaceuticals (REGN) announced Tuesday that sales of its new drug, Eylea, were between $24 million and $24 million during the fourth quarter.
Regeneron Pharmaceuticals gapped open sharply higher Tuesday, but moved in a narrow range throughout the session. The stock finished up by 8.96 at $74.44 and closed challenging the highs of the year, trading at a 3 1/2 month high.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.